Romana Tandara Haček
Research Subjects
Romana Tandara Haček has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Darija Erčević
Department for Development, Research, and Health Technology Assessment, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia
2 shared publications- Michal Stanak
Masaryk University
2 shared publications - Piotr Szymański
Department of Acquired Cardiac Defects, Institute of Cardiology, Warsaw, Poland
2 shared publications - Renata Grenković
Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia
2 shared publications - Sabine Ettinger
HTA Austria – Austrian Institute for Health Technology Assessment GmbH (AIHTA), Vienna, Austria
2 shared publications Claudia Wild
Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, Austria,
1 shared publication
Latest Publications
- Open Access
- 1 January 2019
- Published by Taylor & Francis in Medical Devices: Evidence and Research
- Vol. 12, 129-131
Reply to: Comments on the authors' reply to the critical appraisal concerning "Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study"
Reply to: Comments on the authors' reply to the critical appraisal concerning "Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study" Sabine Ettinger,1 Michal Stanak,1 Piotr Szymański,2 Claudia Wild,1 Romana Tandara Haček,3 Darija Erčević,3 Renata Grenković,3 Gregor Goetz,1 Mirjana Huić3 1Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, Austria; 2Institute of Cardiology, Warsaw, Poland; 3Department for Development, Research, and Health Technology Assessment, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, CroatiaAlthough we clearly outlined our answers in our previous letter,1 we are pleased to clarify further any remaining open issues. There might be diverse views with regard to comparators of the wearable cardioverter defibrillator (WCD). We would like to refer the readers to our previous answer,1 where we explained our rationale for choosing the implantable cardioverter defibrillator as one of the comparators. It was selected based on broad indications stated in the CE mark and after discussions with clinicians. Furthermore, in this case, a change of the comparator, ie, the implantable cardioverter defibrillator, would not have led to a different result or conclusion.View the original paper by Ettinger and colleagues.Two previous letters have been published Sperzel et al Sperzel et al
- 1 January 2019
- Published by Taylor & Francis in Medical Devices: Evidence and Research
- Vol. 12, 129-131
Open AccessReply to: Comments on the authors' reply to the critical appraisal concerning "Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study"
Reply to: Comments on the authors' reply to the critical appraisal concerning "Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study" Sabine Ettinger,1 Michal Stanak,1 Piotr Szymański,2 Claudia Wild,1 Romana Tandara Haček,3 Darija Erčević,3 Renata Grenković,3 Gregor Goetz,1 Mirjana Huić3 1Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, Austria; 2Institute of Cardiology, Warsaw, Poland; 3Department for Development, Research, and Health Technology Assessment, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, CroatiaAlthough we clearly outlined our answers in our previous letter,1 we are pleased to clarify further any remaining open issues. There might be diverse views with regard to comparators of the wearable cardioverter defibrillator (WCD). We would like to refer the readers to our previous answer,1 where we explained our rationale for choosing the implantable cardioverter defibrillator as one of the comparators. It was selected based on broad indications stated in the CE mark and after discussions with clinicians. Furthermore, in this case, a change of the comparator, ie, the implantable cardioverter defibrillator, would not have led to a different result or conclusion.View the original paper by Ettinger and colleagues.Two previous letters have been published Sperzel et al Sperzel et al
- Open Access
- 1 November 2017
- Published by Taylor & Francis in Medical Devices: Evidence and Research
- Vol. ume 10, 257-271
Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study
Aim: To summarize the evidence on clinical effectiveness and safety of wearable cardioverter defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest in patients at risk. Methods: We performed a systematic literature search in databases including MEDLINE via OVID, Embase, the Cochrane Library, and CRD (DARE, NHS-EED, HTA). The evidence obtained was summarized according to GRADE methodology. A health technology assessment (HTA) was conducted using the HTA Core Model® for rapid relative effectiveness assessment. Primary outcomes for the clinical effectiveness domain were all-cause and disease-specific mortality. Outcomes for the safety domain were adverse events (AEs) and serious adverse events (SAEs). A focus group with cardiac disease patients was conducted to evaluate ethical, organizational, patient, social, and legal aspects of the WCD use. Results: No randomized- or non-randomized controlled trials were identified. Non-comparative studies (n=5) reported AEs including skin rash/itching (6%), false alarms (14%), and palpitations/light-headedness/fainting (9%) and discontinuation due to comfort/lifestyle issues (16–22%), and SAEs including inappropriate shocks (0–2%), unsuccessful shocks (0–0.7%), and death (0–0.3%). The focus group results reported that experiencing a sense of security is crucial to patients and that the WCD is not considered an option for weeks or even months due to expected restrictions in living a “normal” life. Conclusion: The WCD appears to be relatively safe for short-to-medium term, but the quality of existing evidence is very low. AEs and SAEs need to be more appropriately reported in order to further evaluate the safety of the device. High-quality comparative evidence and well-described disease groups are required to assess the effectiveness of the WCD and to determine which patient groups may benefit most from the intervention.
- 1 November 2017
- Published by Taylor & Francis in Medical Devices: Evidence and Research
- Vol. ume 10, 257-271
Open AccessWearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study
Aim: To summarize the evidence on clinical effectiveness and safety of wearable cardioverter defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest in patients at risk. Methods: We performed a systematic literature search in databases including MEDLINE via OVID, Embase, the Cochrane Library, and CRD (DARE, NHS-EED, HTA). The evidence obtained was summarized according to GRADE methodology. A health technology assessment (HTA) was conducted using the HTA Core Model® for rapid relative effectiveness assessment. Primary outcomes for the clinical effectiveness domain were all-cause and disease-specific mortality. Outcomes for the safety domain were adverse events (AEs) and serious adverse events (SAEs). A focus group with cardiac disease patients was conducted to evaluate ethical, organizational, patient, social, and legal aspects of the WCD use. Results: No randomized- or non-randomized controlled trials were identified. Non-comparative studies (n=5) reported AEs including skin rash/itching (6%), false alarms (14%), and palpitations/light-headedness/fainting (9%) and discontinuation due to comfort/lifestyle issues (16–22%), and SAEs including inappropriate shocks (0–2%), unsuccessful shocks (0–0.7%), and death (0–0.3%). The focus group results reported that experiencing a sense of security is crucial to patients and that the WCD is not considered an option for weeks or even months due to expected restrictions in living a “normal” life. Conclusion: The WCD appears to be relatively safe for short-to-medium term, but the quality of existing evidence is very low. AEs and SAEs need to be more appropriately reported in order to further evaluate the safety of the device. High-quality comparative evidence and well-described disease groups are required to assess the effectiveness of the WCD and to determine which patient groups may benefit most from the intervention.